DE69739689D1 - Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen - Google Patents

Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen

Info

Publication number
DE69739689D1
DE69739689D1 DE69739689T DE69739689T DE69739689D1 DE 69739689 D1 DE69739689 D1 DE 69739689D1 DE 69739689 T DE69739689 T DE 69739689T DE 69739689 T DE69739689 T DE 69739689T DE 69739689 D1 DE69739689 D1 DE 69739689D1
Authority
DE
Germany
Prior art keywords
rsv
attenuated
mutations
recombinant
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739689T
Other languages
English (en)
Inventor
Brian R Murphy
Peter L Collins
Stephen S Whitehead
Alexander A Bukreyev
Katalin Juhasz
Michael N Teng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69739689D1 publication Critical patent/DE69739689D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
DE69739689T 1996-07-15 1997-07-15 Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen Expired - Lifetime DE69739689D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2177396P 1996-07-15 1996-07-15
US4614197P 1997-05-09 1997-05-09
US4763497P 1997-05-23 1997-05-23
PCT/US1997/012269 WO1998002530A1 (en) 1996-07-15 1997-07-15 Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Publications (1)

Publication Number Publication Date
DE69739689D1 true DE69739689D1 (de) 2010-01-21

Family

ID=27361727

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739689T Expired - Lifetime DE69739689D1 (de) 1996-07-15 1997-07-15 Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen

Country Status (12)

Country Link
US (2) US5993824A (de)
EP (2) EP2112220A3 (de)
JP (2) JP4413999B2 (de)
KR (2) KR100894670B1 (de)
CN (1) CN101012454B (de)
AT (1) ATE451451T1 (de)
AU (1) AU3799797A (de)
BR (2) BR9710363A (de)
CA (1) CA2257823A1 (de)
DE (1) DE69739689D1 (de)
ES (1) ES2345643T3 (de)
WO (1) WO1998002530A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7485440B2 (en) * 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
CN101012454B (zh) * 1996-07-15 2011-11-16 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
US6699476B1 (en) * 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
AU739597B2 (en) * 1997-05-02 2001-10-18 Uab Research Foundation, The Attenuation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US6596529B1 (en) * 1997-05-02 2003-07-22 Uab Research Foundation Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
CA2238659C (en) * 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
KR20010030630A (ko) * 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
US20100028377A1 (en) * 1997-09-26 2010-02-04 Medimmune, Llc Recombinant RSV Virus Expression Systems And Vaccines
AU2006200619B2 (en) * 1997-09-26 2007-12-13 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
US6908618B2 (en) 1997-11-10 2005-06-21 University Of Maryland Production of novel bovine respiratory syncytial viruses from cDNAs
WO1999064571A1 (en) 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
KR20060080249A (ko) 1998-06-12 2006-07-07 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
CN1347458A (zh) * 1999-04-13 2002-05-01 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒负链rna病毒疫苗
IL145796A0 (en) * 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7820182B2 (en) 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
CA2378552A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines
MXPA02000490A (es) * 1999-07-13 2004-09-27 Us Gov Health & Human Serv Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
AU6872000A (en) * 1999-09-06 2001-04-10 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
AU2001257001A1 (en) 2000-04-10 2001-10-23 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DE10020505A1 (de) * 2000-04-26 2001-10-31 Conzelmann Karl Klaus RSV NS Proteine antagonisieren die Interferon (IFN) Antwort
AU2001263896A1 (en) 2000-06-23 2002-01-14 Akzo Nobel N.V. Attenuated bovine respiratory syncytial virus
KR100899030B1 (ko) * 2000-06-23 2009-05-21 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 프로모터 인접 유전자로부터 보호적 항원을 발현하는호흡기 신시티움 바이러스 백신
ATE284440T1 (de) * 2000-10-12 2004-12-15 Univ St Louis Mikroben mit einer transkriptionsabbrecher enthaltender dämpfender mutation
JP4268407B2 (ja) * 2000-11-28 2009-05-27 アヴィロン，インコーポレーテッド 組換えｒｓｖウイルス発現系およびワクチン
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
PL213926B1 (pl) 2001-01-19 2013-05-31 Vironovative Bv Wyizolowany ssaczy metapneumowirus o ujemnej pojedynczej nici RNA (MPV), kompozycja immunogenna, wyizolowane kwasy nukleinowe, sposoby wykrywania ssaczego metapneumowirusa, wektor, komórka gospodarza, wyizolowane bialko, przeciwcialo, sposób wirologicznego diagnozowania infekcji MPV, sposób serologicznego diagnozowania infekcji MPV, kompozycja farmaceutyczna, zestaw diagnostyczny oraz zastosowanie kompozycji farmaceutycznej
UA82466C2 (uk) * 2001-07-18 2008-04-25 Бавариан Нордика А/С Спосіб посилення ампліфікації хордопоксвірусу
US20050048030A1 (en) * 2001-09-28 2005-03-03 Raymond Pickles Paramyxoviruses as gene transfer vectors to lung cells
EP1456398B1 (de) 2001-11-21 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
MXPA04008088A (es) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Sistema de expresion del virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metapneumovirus.
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
KR101229202B1 (ko) 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
AU2003270824B2 (en) 2002-09-18 2009-02-19 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
US20040152651A1 (en) * 2002-11-01 2004-08-05 Rana Tariq M. Regulation of transcription elongation factors
US7704491B2 (en) 2003-02-28 2010-04-27 The United States Of America As Represented By The Department Of Health And Human Services Recombinant human metapneumovirus and its use
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
EP1631663B1 (de) 2003-05-28 2016-08-24 Wisconsin Alumni Research Foundation Rekombinante influenza viren mit hohem titer zur impfung und gentherapie
BRPI0411247A (pt) 2003-06-09 2006-07-25 Wyeth Corp processo melhorado para a recuperação de vìrus de rna de filamento negativo não segmentado partindo do cdna
EP1633312A4 (de) 2003-06-16 2012-09-26 Medimmune Llc Influenza-hämagglutinin- und neuraminidase-varianten
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
ES2618523T3 (es) 2003-12-24 2017-06-21 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Volksgezondheid, Welzijn En Sport Virus respiratorio sincitial con una deficiencia genómica complementada in trans
CA2568015C (en) 2004-05-25 2013-08-27 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
ES2694123T3 (es) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
WO2006062701A2 (en) * 2004-11-16 2006-06-15 Janssen Pharmaceutica N.V. Sphingosine kinase-1 mediates gene expression regulation of a monocyte chemoattractant protein-1 gene
CN101103103A (zh) 2004-11-19 2008-01-09 威斯康星旧生研究基金会 具有串联转录单位的重组流感病毒载体
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
WO2006098901A2 (en) 2005-03-08 2006-09-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
TWI531652B (zh) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 表現非原生表面蛋白質之嵌合病毒及其用途
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101586968B1 (ko) 2006-08-09 2016-01-20 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
WO2008121992A2 (en) 2007-03-30 2008-10-09 Research Foundation Of State University Of New York Attenuated viruses useful for vaccines
CN101715487A (zh) 2007-06-18 2010-05-26 米迪缪尼有限公司 血凝素多肽中有变化的b型流感病毒
WO2008156778A2 (en) 2007-06-18 2008-12-24 Tokiko Watanabe Influenza m2 protein mutant viruses as live influenza attenuated vaccines
US20090017517A1 (en) * 2007-07-13 2009-01-15 Medimmune, Llc Preparation of Negative-Stranded RNA Viruses by Electroporation
WO2010003032A2 (en) * 2008-07-01 2010-01-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health A Recombinant human parainfluenza type 1 viruses (hpiv1s) containing mutations in or deletion of the c protein are attenuated in african green monkeys and in ciliated human airway epithelial cells and are potential vaccine candidates for hpiv1
US8591914B2 (en) 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5644502B2 (ja) 2008-11-05 2014-12-24 旭硝子株式会社 含フッ素弾性共重合体、その製造方法および架橋ゴム
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
JP5818693B2 (ja) 2009-02-12 2015-11-18 メディミューン，エルエルシー インフルエンザ赤血球凝集素およびノイラミニダーゼ変異体
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US8597637B1 (en) * 2010-05-18 2013-12-03 Weidong Zhang Breast cancer therapy using an engineered respiratory syncytial virus
US9044499B1 (en) 2010-06-22 2015-06-02 Weidong Zhang NS1/2-deficient respiratory syncytial virus and melanoma treatment
CN104185476A (zh) 2011-09-20 2014-12-03 西奈山医学院 流感病毒疫苗及其应用
ES2863477T3 (es) 2012-04-13 2021-10-11 Us Health Vacuna genéticamente estable viva atenuada contra el virus respiratorio sincitial y su producción
US9968670B2 (en) 2012-12-18 2018-05-15 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
ES2952387T3 (es) 2013-02-08 2023-10-31 Us Health Atenuación del virus respiratorio sincitial humano mediante la desoptimización de pares de codones a escala genómica
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105189756B (zh) 2013-03-14 2021-06-11 爱默蕾大学 具有沉默突变的重组rsv、其相关疫苗和方法
MY180687A (en) 2013-03-14 2020-12-07 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
US9950057B2 (en) 2013-07-15 2018-04-24 Wisconsin Alumni Research Foundation (Warf) High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
KR20160044566A (ko) * 2013-08-21 2016-04-25 큐어백 아게 호흡기 세포융합 바이러스
CN103789276B (zh) * 2014-01-14 2015-12-09 昆明理工大学 一种呼吸道合胞病毒减毒毒株及其应用
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
JP6336044B2 (ja) * 2014-04-10 2018-06-06 株式会社Ｊｏｌｅｄ 有機ｅｌ表示パネルの製造方法
WO2015196150A2 (en) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
CN107406835A (zh) 2015-01-20 2017-11-28 美利坚合众国,由健康及人类服务部部长代表 表达嵌合rsv/bpiv3f蛋白的重组人/牛副流感病毒3(b/hpiv3)及其用途
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
EP3337504A1 (de) 2015-08-20 2018-06-27 University of Rochester Lebend attenuierter impfstoff mit mutationen in viraler polymerase zur behandlung und prävention des hundeinfluenzavirus
US10548966B2 (en) 2015-08-20 2020-02-04 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
BR112018008708A2 (pt) 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3026256A1 (en) 2016-06-03 2017-12-07 University Of Rochester Equine influenza virus live-attenuated vaccines
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
EP3515930A1 (de) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Impfstoffkandidaten für humanes respiratorisches synzytialvirus (rsv) mit abgeschwächten phänotypen
EP3606555A4 (de) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN107384958B (zh) * 2017-07-14 2020-04-10 北京交通大学 基于反向遗传学构建的rsv反基因组质粒及其应用
WO2019168911A1 (en) 2018-02-27 2019-09-06 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
WO2020167432A2 (en) 2019-01-23 2020-08-20 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CA3130781A1 (en) 2019-02-27 2020-09-03 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3224404A1 (de) 1982-06-30 1984-01-05 LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl Reibungskupplung sowie verfahren zu deren montage
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800078A (en) 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
GB9200117D0 (en) 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
ATE257175T1 (de) * 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US20030054505A1 (en) 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
AU712213B2 (en) 1995-09-22 1999-11-04 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
US6077514A (en) 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
CN101012454B (zh) 1996-07-15 2011-11-16 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒呼吸道合胞病毒疫苗的方法
US6699476B1 (en) * 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CA2291216A1 (en) 1997-05-23 1998-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
WO1999002657A1 (en) 1997-07-11 1999-01-21 Yale University Rhabdoviruses with reengineered coats
US6364957B1 (en) * 1997-10-09 2002-04-02 Applied Materials, Inc. Support assembly with thermal expansion compensation
AU1297299A (en) 1997-11-10 1999-05-31 University Of Maryland Production of novel bovine respiratory syncytial viruses from cdnas
IL145796A0 (en) 1999-04-13 2002-07-25 Us Health Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
CN1347458A (zh) 1999-04-13 2002-05-01 美国政府健康及人类服务部 从克隆的核苷酸序列制备减毒负链rna病毒疫苗
AU5918100A (en) 1999-07-09 2001-01-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
MXPA02000490A (es) 1999-07-13 2004-09-27 Us Gov Health & Human Serv Produccion de virus sincitiales respiratorios recombinantes, que expresan moleculas inmunomoduladoras.
US9615524B2 (en) 2015-04-17 2017-04-11 Pop Vriend Research Bv Garden bean variety PV-832

Also Published As

Publication number Publication date
BRPI9710363B1 (pt) 2011-11-16
BR9710363A (pt) 2000-01-11
CN101012454B (zh) 2011-11-16
JP2008283984A (ja) 2008-11-27
JP2002511731A (ja) 2002-04-16
BRPI9710363B8 (pt) 2021-07-06
US7709007B2 (en) 2010-05-04
EP2112220A2 (de) 2009-10-28
CN101012454A (zh) 2007-08-08
KR100658491B1 (ko) 2006-12-18
KR20060015658A (ko) 2006-02-17
BRPI9710363A (pt) 2000-01-11
EP0912724B1 (de) 2009-12-09
CA2257823A1 (en) 1998-01-22
ATE451451T1 (de) 2009-12-15
KR100894670B1 (ko) 2009-04-22
US20060159703A1 (en) 2006-07-20
US5993824A (en) 1999-11-30
EP0912724A1 (de) 1999-05-06
JP4413999B2 (ja) 2010-02-10
KR20000023802A (ko) 2000-04-25
EP2112220A3 (de) 2010-01-06
ES2345643T3 (es) 2010-09-28
AU3799797A (en) 1998-02-09
WO1998002530A1 (en) 1998-01-22

Similar Documents

Publication Publication Date Title
DE69739689D1 (de) Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
WO2000061611A3 (en) Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
KR100850620B1 (ko) 약독된 생백신
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
GEP20022695B (en) Moraxella Catarrhalis Outer Membrane Protein-106 Polypeptide, Gene Sequence and Uses Thereof
UA41315C2 (uk) Вакцинна композиція проти респіраторно-синцитіального вірусу, спосіб стимулювання імунної системи індивідуума для індукції захисту проти респіраторно-синцитіального вірусу
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
Hilleman Newer directions in vaccine development and utilization
JP2001516583A5 (de)
EP1323428A3 (de) Avirulente Salmonella Mikroben und ihre Verwendung
CA2533877A1 (en) Safe mutant viral vaccines
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
DK8789A (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
WO1995012682A3 (en) Viral vector with bovine viral diarrhea virus (bvdv) antigens
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
WO2001010469A3 (en) Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their use as vaccines
Möst et al. Recombinant versus plasma-derived hepatitis B vaccine: comparison of immunogenicity in medical students
SI1200122T1 (sl) Večkomponentno cepivo za zaščito pred boleznijo, ki jo povzročata Haemophilus influenzae in Moraxella catarrhalis
BR0112276A (pt) Vìrus sincicial respiratório recombinante infeccioso isolado, método para estimular o sistema imune de um indivìduo para induzir proteção contra rsv, composição imunogênica e molécula de polinucleotìdeo isolado
DK1074266T3 (da) Levende svækkede bakterier til anvendelse i vaccine

Legal Events

Date Code Title Description
8364 No opposition during term of opposition